Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.
- 1 January 1987
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 5 (1) , 55-61
- https://doi.org/10.1200/jco.1987.5.1.55
Abstract
Univariate and multivariate analyses of potential prognostic factors for 1,015 women with recurrent breast cancer confirmed that the site of initial recurrence is an important determinant for predicting survival from the time of initial recurrence. However, both estrogen receptor (ER) status and axillary lymph node status at diagnosis, as well as the length of the disease-free interval, provide additional independent information for predicting patient survival after disease recurrence. Involved axillary lymph nodes at the time of initial diagnosis and/or lack of ERs may indicate a highly malignant tumor or a weak host defense, either of which might be related to short survival after relapse. Patients with ER-negative tumors recurred more often in visceral and soft-tissue sites, while patients with ER-positive tumors were more likely to recur in bony sites. However, for each metastatic site, receptor-positive patients had longer survivalThis publication has 14 references indexed in Scilit:
- Southeastern cancer study group: Breast cancer studies 1972–1982International Journal of Radiation Oncology*Biology*Physics, 1983
- Multivariate analysis of prognostic factors in metastatic breast cancer.Journal of Clinical Oncology, 1983
- Oestrogen-receptor status and sites of metastasis in breast cancerBritish Journal of Cancer, 1981
- Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancerPublished by Elsevier ,1981
- RELATIONSHIPS OF S-PHASE FRACTION OF BREAST-CARCINOMA IN RELAPSE TO DURATION OF REMISSION, ESTROGEN-RECEPTOR CONTENT, THERAPEUTIC RESPONSIVENESS, AND DURATION OF SURVIVAL1980
- Advanced breast cancer: Are the traditional stratification parameters still of value when patients are treated with combination chemotherapy?Published by Elsevier ,1979
- PROGNOSTIC FACTORS IN METASTATIC BREAST-CANCER TREATED WITH COMBINATION CHEMOTHERAPY1979
- EVALUATION OF ESTROGEN-RECEPTOR ASSAYS IN HUMAN BREAST-CANCER TISSUE1977
- CLINICAL STAGES OF BREAST CANCER - WHAT DO THEY MEAN1967
- ADVANCED BREAST CARCINOMA-FACTORS INFLUENCING SURVIVAL1963